National Bank of Canada
IBRX icon

National Bank of Canada’s ImmunityBio IBRX Stock Holding History

National Bank of Canada’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.33M Buy
8,249
+7,402
+874% +$50.7K 0.01% 800
2025
Q4 		$168K Sell
847
-227
-21% -$514 ﹤0.01% 1638
2025
Q3 		$264K Sell
1,074
-1,816
-63% -$4.68K ﹤0.01% 1480
2025
Q2 		$763K Sell
2,890
-2,030
-41% -$5.46K ﹤0.01% 1338
2025
Q1 		$1.48M Sell
4,920
-3,297
-40% -$9.99K ﹤0.01% 1118
2024
Q4 		$2.1M Sell
8,217
-2,687
-25% -$11.2K ﹤0.01% 1156
2024
Q3 		$4.06M Buy
10,904
+3,637
+50% +$16.8K ﹤0.01% 884
2024
Q2 		$4.56M Buy
7,267
+3,931
+118% +$25.9K 0.01% 763
2024
Q1 		$2.71M Buy
+3,336
New +$15.1K ﹤0.01% 957
2023
Q4 		– Sell
-7,716
Closed -$1.18M – 2801
2023
Q3 		$1.18M Sell
7,716
-2,540
-25% -$5.1K ﹤0.01% 1155
2023
Q2 		$2.81M Buy
10,256
+8,953
+687% +$25.3K 0.01% 898
2023
Q1 		$237K Hold
1,303
– – ﹤0.01% 1371
2022
Q4 		$661K Buy
+1,303
New +$7.16K ﹤0.01% 1201

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

National Bank of Canada's IBRX Position: Q1 2026 in Review

National Bank of Canada increased its ImmunityBio (IBRX) stake by 619% in Q1 2026, buying an estimated $3.59M and bringing the position to 608,774 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #876.

National Bank of Canada first reported a position in IBRX in Q4 2021 and has held it in 16 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • National Bank of Canada held 608,774 shares of ImmunityBio worth $4.67M as of Q1 2026.
  • National Bank of Canada bought 524,074 ImmunityBio shares in Q1 2026, an estimated $3.59M.
  • ImmunityBio made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #876 holding.
  • National Bank of Canada first reported a position in ImmunityBio in Q4 2021 and has held it in 16 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.